Effect of iron chelators with potent anti-proliferative activity on the expression of molecules involved in cell cycle progression and growth.
Gao
J
J
Department of Medicine, Royal Brisbane Hospital, Herston, Queensland, Australia.
Lovejoy
D
D
Richardson
D R
DR
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle; D019938:Cyclin D1 / Q000032:analysis; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000235:genetics; D003676:Deferoxamine / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D007502:Iron Chelating Agents / Q000494:pharmacology*; D009687:Nuclear Proteins; D011506:Proteins / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics; D051736:Proto-Oncogene Proteins c-mdm2; D016160:Retinoblastoma Protein / Q000378:metabolism; D014407:Tumor Cells, Cultured; D000097642:GADD45 Proteins
D000970:Antineoplastic Agents; D019938:Cyclin D1; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D003676:Deferoxamine; D047908:Intracellular Signaling Peptides and Proteins; D007502:Iron Chelating Agents; D009687:Nuclear Proteins; D011506:Proteins; D011518:Proto-Oncogene Proteins; D051736:Proto-Oncogene Proteins c-mdm2; D016160:Retinoblastoma Protein; D000097642:GADD45 Proteins; C493956:CDKN1A protein, human; C497206:MDM2 protein, human